A common germline deletion in the BIM gene was recently shown to favor the production of non-apoptotic BIM isoforms, and to predict inferior responses in TKI-treated chronic myeloid leukemia (CML) and EGFR-driven lung cancer patients. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.